Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-714-0360
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics Inc (NASDAQ:LPTX) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.06. View Leap Therapeutics' Earnings History.
When is Leap Therapeutics' next earnings date?
What price target have analysts set for LPTX?
2 analysts have issued 1-year price targets for Leap Therapeutics' stock. Their forecasts range from $8.00 to $13.00. On average, they anticipate Leap Therapeutics' stock price to reach $10.50 in the next year. This suggests a possible upside of 414.7% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.
What is the consensus analysts' recommendation for Leap Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.
Has Leap Therapeutics been receiving favorable news coverage?
Press coverage about LPTX stock has been trending negative on Thursday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Leap Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Leap Therapeutics.
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include Spero Therapeutics (SPRO), Poxel (PXXLF), Chimerix (CMRX), Galectin Therapeutics (GALT), American Brivision (Holding) (ABVC), REDHILL BIOPHAR/S (RDHL), TAIWAN LIPOSOME/S (TLC), Axovant Gene Therapies (AXGT), Nature's Sunshine Products (NATR), Calithera Biosciences (CALA), Newron Pharmaceuticals (NWPHF), BioXcel Therapeutics (BTAI), Adamas Pharmaceuticals (ADMS), Ardelyx (ARDX) and LifeVantage (LFVN).
What other stocks do shareholders of Leap Therapeutics own?
Who are Leap Therapeutics' key executives?
Leap Therapeutics' management team includes the folowing people:
- Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
- Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
- Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)
How do I buy shares of Leap Therapeutics?
Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Leap Therapeutics' stock price today?
One share of LPTX stock can currently be purchased for approximately $2.04.
How big of a company is Leap Therapeutics?
Leap Therapeutics has a market capitalization of $46.82 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.
What is Leap Therapeutics' official website?
How can I contact Leap Therapeutics?
Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.
MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
